BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

Pfizer Inc.'s COVID-19 vaccine is on track to generate a whopping $26 billion in sales this year, making it the drug maker's top-selling drug and forging a new path into infectious diseases for the legacy drug maker.

Pfizer's next play: A vaccine maker and pandemic ‘partner' to governments

BioNTech SE Sponsored ADR (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

BioNTech SE Sponsored ADR (BNTX) Stock Jumps 11%: Will It Continue to Soar?

Full FDA approval would allow the vaccine to be administered after the Covid-19 pandemic ends.

Pfizer Will File For Full FDA Approval For Covid-19 Vaccine By End Of May

Pfizer Inc. significantly increased revenue projections from its Covid-19 vaccine for the year, as sales from the shot over the first three months of 2021 lifted the company to a stronger quarterly profit.

Pfizer's COVID-19 vaccine lifts quarterly results

Mainz, Germany, Ma y 4 , 2021 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2021 on Monday, May 10th, 2021. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the first quarter 2021.

BioNTech to Report First Quarter 2021 Financial Results and Operational Update on May 10, 2021

The Food and Drug Administration has plans to authorize the emergency use of Pfizer Inc (NYSE: PFE) and BioNTech SE's (NASDAQ: BNTX) jointly-developed COVID-19 vaccine in adolescents aged between 12 to 15 years, the New York Times reported Monday. What Happened: The move means that the campaign to vaccinate against COVID-19 will potentially expand to millions more, as per the Times.

Pfizer COVID-19 Vaccine Expected To Get FDA Emergency Approval For Age Group 12-15 Next Week

Pfizer Inc. PFE is expected to get Food and Drug Administration approval for use of its COVID-19 vaccine in children aged 12 to 15, according to a report late Monday. Unnamed federal officials told The New York Times that the approval could come as early as late this week.

Pfizer COVID-19 vaccine to be approved for 12- to 15-year olds: report

The Food and Drug Administration is set to authorize the use of the Pfizer-BioNTech COVID-19 vaccine for adolescents aged 12-15 years old as early as next week, The New York Times reported Monday. Following FDA authorization, an advisory panel from the Centers for Disease Control and Prevention will review data and results from clinical trials to draft recommendations on the use of the vaccine for those 12-15 years old, according to The Times report.

FDA to authorize the use of the Pfizer COVID-19 vaccine for those ages 12-15 as early as next week, The New York Times reports

We expect Pfizer to likely post revenue and earnings above the consensus estimates, primarily led by its Covid-19 vaccine.

All Eyes On Covid-19 Vaccine Contribution As Pfizer Reports Its Q1

Shares of Pfizer Inc. gained 2.2% in trading on Monday after the pharmaceutical company said it will donate $70 million in medicine to India, which is facing the worst surge in COVID-19 cases worldwide during the pandemic. The drugmaker also reiterated that the COVID-19 vaccine it developed with BioNTech SE has not yet been approved in India, though the application was "submitted months ago.

Pfizer says it submitted application for COVID-19 vaccine to Indian regulators 'months ago'

The stock price of BioNTech SE (NASDAQ: BNTX) increased from $188.28 to $198.11 (up 5.22%) as of 6:11 AM ET. This is why it happened.

BNTX Stock: From $188.28 To $198.11 (5.22% Increase) Pre-Market Explanation

Moderna

Both vaccines do an impressive job of providing protection against COVID-19. But Moderna's is much easier to get from production facilities into patients' arms.

Moderna Just Made the Pfizer Vaccine's Biggest Weakness an Even Bigger One

The two companies stand an excellent chance of winning expanded authorization in Europe for their coronavirus vaccine.

Why Pfizer and BioNTech Shot Higher on Friday

The protection from the first dose is “significantly enhanced” if someone has already had Covid.

Single Pfizer Vaccine Shot May Not Protect Against Covid Variants, Study Warns

According to a U.K. study, a single dose of Pfizer Inc (NYSE: PFE) - BioNTech SE's (NASDAQ: BNTX) coronavirus vaccine may not generate a sufficient immune response to protect against dominant new variants, except in people who have already been infected with COVID-19, reports Reuters. The Imperial College-led study, which analyzed blood samples among healthcare workers after their first dose of the Pfizer shot, found that those who previously had the infection showed better protection against virus variants found in Britain and South Africa.

Two Doses Pfizer-BioNTech COVID-19 Vaccine Necessary To Generate Immune Response Against Variants, UK Study Show: Reuters

2 Doses Pfizer-BioNTech COVID-19 Vaccine Necessary To Generate Immune Response Against Variants, UK Study Show: Reuters

Pfizer and BioNTech have asked for authorization from the European Medicines Agency to use their COVID-19 vaccines in kids ages 12-15. Children in the European Union might be eligible to roll up their sleeves soon.

Pfizer and BioNTech want to vaccinate European kids ages 12-15

Young children could get vaccinated by the end of the year, Dr. Ozlem Tureci, the co-founder and chief medical officer of BioNTech, told CNBC.

BioNTech expects Covid vaccine data on kids ages 5 to 11 as early as end of summer

The companies have already asked the FDA to expand its license to cover some children in the U.S..

Pfizer, BioNTech Seek Approval To Extend Covid-19 Vaccine For Use Among Teenagers

BioNTech and Pfizer seek European OK to use COVID vaccine in kids as young as 12

NEW YORK a nd MAINZ, GERMANY , April 30 , 202 1 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have submitted a variation to the Conditional Marketing Authorization (CMA) in the European Union (EU) to the European Medicines Agency (EMA) for the Pfizer-BioNTech vaccine COMIRNATY® (BNT162b2) to request an extension of the indication for use in adolescents 12 to 15 years of age. If EMA approves the variation, the amended CMA will be valid in all 27 member states of the EU. The companies have already submitted a similar request to the U.S. Food and Drug Administration (FDA) for the Emergency Use Authorization (EUA) and plan to request additional amendments with other regulatory authorities worldwide.

Pfizer and BioNTech Submit Request to Expand Conditional Marketing Authorization of COMIRNATY® in the EU to Adolescents

Arcturus Therapeutics

CureVac B.V

Probably not, but at least one of them could make you thousands over time.

Could These 3 Brilliant mRNA Stocks Make You Millions?

Pfizer Inc. (NYSE: PFE) has started exporting COVID-19 vaccine doses produced in its U.S. plant to Mexico, Reuters reported Thursday, citing a person familiar with the matter. What Happened: The shipment of vaccine doses from Pfizer's Kalamazoo, Michigan plant to Mexico is the first export from the U.S. by the drugmaker after a restriction on dose exports by the former President Donald Trump's administration expired at the end of March, as per the Reuters report.

Pfizer Said To Have Begun Exporting US-Made COVID-19 Vaccine

BioNTech CEO Ugur Sahin told CNBC he is "confident" the company's Covid-19 vaccine with Pfizer is effective against a variant first identified in India

BioNTech CEO confident Covid vaccine works against 'double mutant' strain identified in India

Loncar China Biopharma ETF

Loncar Cancer Immunotherapy ETF

CRISPR Therapeutics

Editas Medicine

iShares Nasdaq Biotechnology ETF

Telesis Bio Inc

SPDR S&P Biotech ETF

Here is what you should know about investing in these life changing technologies.

News for BioNTech SE Stock (BNTX)